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IN GENERAL oestrogen receptor (RE)
and progesterone receptor (RP) tend to
occur together in breast carcinomas, RP
being a marker of RE integrity (Horwitz
et al., 1975a). It has also been claimed that
RP is associated with a lower risk of
distant metastatic spread (Pichon et al.,
1980).
The starting point for this work was a
small group of tumours that seemed to
deviate from this general rule; RP- and
RE+. It has been shown (Thorsen, 1981)
that heparin may interfere with the esti-
mation of RP in vitro. It has further been
shown (Hartveit, 1981) that mast cells are
common at the edge ofbreast carcinomas,
in association with infiltrative growth. As
tissue from the latterprovides the material
for the cytosol used in receptor determina-
tion, and as mast cells are a potent source
of heparin (see review by Riley, 1954) it
occurred to one of us (F.H.) that the
indigenous heparin might be interfering
with the receptor assay. This idea was
tested by comparing the mast-cell counts
in the tumour tissue with the results of
receptor assay.
The patients providing the material for
this study all had infiltrating breast
carcinomas, treated by modified radical
mastectomy at 2 local surgical units. None
had pre-operative irradiation or chemo-
therapy.
Material from the primary tumours had
been taken at the time of operation, and
divided, one part being used for receptor
determination, one for histology. Both
receptors were analysed by dextran-
charcoal assay (DCA) (McGuire et al.,
1975; Horwitz et al., 1975b). Although
cytosols were no longer available, a total
of 186 paired samples (i.e. RE and RP
values and the corresponding histological
material) were.
From this material we selected all the
RP- RE- cases (17), all the RP- RE+ (18)
and the first 29 of the RP+ RE+. Values
> 3 fmol/mg cytosol were considered posi-
tive for RE, > 5 fmol for RP. The age of
the patients ranged from 33 to 91 years
with a mean of 64. Only 9 of them were
under 55. There was no difference in age
distribution between the groups.
Sections from the formalin-fixed para-
ffin-embedded blocks from the primary
tumours were stained with toluidine blue
at pH4 (Hartveit, 1981). The mast cells
were counted at the edge of the tumour
(in the zone of host-tumour interaction)
using light microscopy (x 400). The
microscope was connected to a digitizer
(Summagraphic: Bit pad one) which in
turn was connected to a computer, as
described previously (Thoresen et al.,
1982). One slide was used per case and
the total number of mast cells in 20 fields
was counted.
The mean values ( s.d.) for the mast-
cell count were related to the receptor
profile of the tumours, as judged from
cytosol assay. The profile RP+ RE- is not
included, as we had only 3 such cases.
The figure shows the range and distri-
bution of the mast-cell counts in thePROGESTERONE RECEPTOR AND MAST-CELL CONTENT
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FIG. The distribution of the mast-cell
counts in 64 cases of breast cancer relatedl
to receptor profile.
individual cases in the 3 groups. The
scatter was great in all groups. Inspection
ofthe figure shows that a line dividing the
material at 40 mast cells/20 high-power
fields divides the group RP- RE+ almost
in half, while only one value lies over 40 in
each ofthe other groups. This difference is
statistically significant (X2 giving P <
0X001). In the 29 tumours with the com-
mon profile RP+ RE-, the mean mast-cell
count in 20 high-power fields ( ± s.d.) was
13 + 14. That in the RP- RE+ group of 17
tumours was similar (8 + 16). The mean
mast-cell count was significantly higher
in the 18 tumours with the profile RP-
RE+ (t test corrected for small samples
gives P < 0.005). No relationship was
found between the exact RP values and
the mast-cell counts.
Heparin is one of the main products of
mast cells, and it has been claimed that
they are the only source of this substance.
It has further been shown that there is
good correlation between the mast-cell
content of a particular tissue and the
amount of heparin that can be extracted
from it (Holmgren et al., 1937; Jorpes,
1937).
The reported frequency of specific pro-
gesterone receptor in human breast carci-
noma varies from - 40% (Skinner et al.,
1980) to 60% (Horwitz etal., 1975a). In our
material it is 55%0 (Thorsen, unpublished).
In keeping with the theory that the syn-
thesis of RP depends on the action of
oestrogen, Horwitz et al. (1975a) found
that RP+ tumours showed a higher fre-
quency of regression after endocrine
therapy than their RP- counterparts.
Accordingly, the presence of RP may give
a more accurate indication of a tumour's
potential response to endocrine therapy
than the presence of RE alone, though
RP- tumours sometimes respond (Barnes
etal., 1977).
When heparin is added to tumour
cytosol containing RP suppression of the
binding of R5020 occurs in the DCA
(Thorsen, 1981). On the basis of the high
mast-cell counts in the RP- RE+ samples,
the negative RP values may thus be false
negatives, a result of the action of the
indigenous heparin rather than lack ofRP.
The low mast-cell counts in the RP- RE-
cytosols indicate that the RP- results may
be acceptable on the face values, i.e. that
the tumours really do lack RP. This would
be in keeping with the previously stressed
interdependence of RE and RP.
A further possible source of false-
negative results is a low level ofcirculating
oestrogen, with subsequent failure to
generate RP. King (1980) found that
postmenopausal women had a higher
proportion of RP- tumours than pre-
menopausal women, and explained this on
the basis of low oestrogen levels in the
former. But Lesser et al. (1981) found no
significant variation with menstrualstatus,
in keeping with the findings from 270 cases
investigated here (Thorsen, unpublished).
The lack of correlation between the
actual RP values and the mast-cell counts
stress that no quantitative assessment can
be given. This is in keeping with lack of
correlation between the actual RE values
and other parameters (Thoresen et al.,
1981).
The present work suggests that due
account should be taken of the tumour
mast-cell content before a negative RP
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report is accepted. Patients with tumours
with a RP- RE+ profile could theoretic-
ally react favourably to endocrine therapy.
It will also be necessary to differentiate
carefully between the groups RP-, RE-
and RP- RE+ before any prognostic
significance is attached to the absence of
RP. Finally, the possibility that the
prognostic significance attached to lack of
RP (Pichon et al., 1980) should rather be
attributed to the tumour mast-cell con-
tent cannot be dismissed, but needs further
evaluation that is outside the scope of the
present paper.
Our thanks are (Itde to the xvaiious surgeons at, thle
Surgical Department of the University Hospital andl
the Deaconess Hospital, here, w%vho sent tus the
specimens for investigation.
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